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Abstract 
Stimulus-induced drug delivery systems and nanotechnology allow selective targeting of 
disease-affected tissues in order to improve pharmacokinetic properties of therapeutics while 
minimizing adverse events associated with systemic exposure. The objective of this research 
was to explore Eudragit L-100, a pH sensitive co-polymer comprised of methacrylic acid and 
methyl methacrylate, in the fabrication of nanoparticles (NPs) that efficiently accumulate in 
alveolar macrophages and preferentially release the payload in Mycobacteria tuberculosis (TB)-
infected lysosomes. The lipophilic fluorescent dye Rhodamine123 (Rh123) was selected as a 
surrogate for the anti-TB agent rifampicin. Eudragit L-100 NPs were prepared using the 
nanoprecipitation technique, which afforded colloids with a hydrodynamic diameter between 
238-270 nm and a zeta potential ranging from –21.8 to –33.1 mV. Subsequent in vitro release 
experiments performed in phosphate-buffered saline at pH 5.5, 6.2 and 7.4 demonstrated pH-
dependent release kinetics of Rh123 from NPs. In comparison to pH 5.5, the cumulative amount 
of Rh123 released was approximately 3-fold greater at pH 6.2 and 6-fold increased at pH 7.4. 
Regression analyses using various mathematical models suggested predominant contribution of 
passive diffusion in Rh123 release at pH 5.5, with increasing assistance of carrier erosion at pH 
6.2 and 7.4. Incubation of the mouse alveolar macrophage (MH-S) cell line with Rh123-
containing NPs revealed a 50% decrease in cellular viability at NP concentrations of 2.8 
mg/mL. Consequently, cellular uptake experiments were performed using a NP concentration of 
1.62 mg/mL where viability > 99.9% was guaranteed. To simulate less acidic lysosomal pH 
conditions of TB-infected macrophages, MH-S cells were exposed to NH4Cl concentrations up 
to 100 mM. Only the highest NH4Cl concentration increased the lysosomal pH of MH-S cells 
from resting pH 5.5 to the desired pH 6.2. Cellular uptake of Rh123-containing Eudragit L-100 
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NPs was assessed spectrophotometrically using NH4Cl- and vehicle-treated control cells. 
Interestingly, intracellular Rh123 concentrations were significantly decreased in NH4Cl-treated 
cells. As confocal microscopy was unable to distinguish intracellular distribution pattern 
between NP-associated and dissolved Rh123, alternative methodologies must be explored to 
determine whether less acidic lysosomal pH alters the release of Eudragit L-100 NP payload in 
TB-infected macrophages. 
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1. Introduction 
1.1. The Threat of Tuberculosis in the 21st Century 
1.1.1. Tuberculosis Prevalence and Pathogenicity 
Tuberculosis (TB) is one of the deadliest diseases around the world. According to the U.S. 
Center of Disease Control and Prevention (CDC), approximately 9 million cases were reported 
in 2013 worldwide, which resulted in estimated 1.5 million tuberculosis-related deaths. In the 
same year, 9,582 TB cases were reported in the U.S., which translates into an incidence rate of 
3.0 cases per 100,000 people (CDC, 2013). Tuberculosis is a bacterial infection caused by the 
rod-shaped Mycobacterium tuberculosis bacillus. Unlike other pathogenic bacteria, TB bacilli 
possess a unique cell envelope composed of complex lipids contributing to ~60% of their total 
weight (Torrelles et al., 2010). The complex cell envelope of M. tuberculosis can be divided 
into two main structures: the capsule-like outermost layer and cell wall (Brennan, 2003). A 
schematic structure of the M. tuberculosis cell wall is shown in Figure 1. 
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Figure 1: Cell wall structure of Mycobacterium tuberculosis.                                                                           
(Adapted from http://2009.igem.org/Team:SupBiotech-Paris/Concept1) 
 
The capsule-like layer contains proteins, carbohydrates, and lipids forming the unique mycolyl-
arabinogalactan-peptidoglycan complex of the cell wall. These surface structures tend to shed 
and/or cleave upon contact with the host cells. The surface of M. tuberculosis is rich in 
mannose–derived molecules such as mannan, mannose-capped lipoarabinomannan, lipomannan, 
arabinomannan, phosphatidyl-myoinositol mannosides, and mannoglycoproteins. The 
molecules facing the exterior of the cell surface act as ligands for alveolar macrophages 
receptors (Torreles et al., 2010). Furthermore, this lipid-rich shield effectively decreases 
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permeation of therapeutic agents, which significantly contributes to the difficulty of eradicating 
mycobacterial infections. 
Although M. tuberculosis can infect any tissue in the body, the lungs represent the main route of 
pathogen entry and are the sites of most common disease manifestation. TB spreads through 
microorganism-containing droplets that are expelled by patients suffering from active disease 
while coughing. 
According to the statistics compiled by the World Health Organization (WHO), less than 10% 
of infected patients will develop active disease during their lifetime. However, in the absence of 
appropriate treatment, 50% of these cases will be fatal. TB is more deleterious in patients with 
compromised immunity due to other underlying conditions, including diabetes mellitus, HIV 
infection, and malnourishment. In adults, reactivation of a latent infection is the major cause of 
developing disease symptoms. In immunocompromised individuals, newborns, and the elderly 
population, disease manifestations typically occur after first exposure to the bacteria (WHO, 
2015).  
1.1.2. Therapeutic Strategies 
Conventional pharmacological approaches in tuberculosis treatment focus on drug regimens 
with rifampicin and isoniazid, which represent the two most important antibiotics. To reduce the 
possibility of drug resistance and treatment failure, they can be prescribed together with 
pyrazinamide and/or ethambutol. These four drugs are considered first-line treatment against 
TB. Clinical success of this regimen requires patients to adhere to this combination for two 
months, followed by additional four months of rifampicin and isoniazid (Walker et al., 2011). 
Isoniazid is a water–soluble anti-TB agent. It is a prodrug activated by catalase-peroxidase to 
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produce several therapeutically effective species, including reactive oxygen radicals such as 
superoxides and peroxides as well as isonicotinic acyl intermediates. These molecules target the 
TB enoyl-acyl carrier protein reductase, which plays a central role in the biosynthesis of 
mycolic acid (Shoeb et al., 1985). Rifampicin, in contrast, is a lipid- soluble antibiotic that binds 
to the β-subunit of bacterial RNA polymerase, thus, blocking formation of RNA chains. 
Pyrazinamide is also a prodrug that is converted by M. tuberculosis pyrazinamidase enzyme to 
pyrazinoic acid. This active metabolite accumulates inside the microorganism and causes 
acidification of the cytoplasm, which effectively reduces the cell membrane potential leading to 
permanent impairment of vital membrane transport function (Zhang et al., 2003). Ethambutol is 
a bacteriostatic drug that inhibits arabinan, arabinogalactan, and lipoarabinomannan 
polymerization, thus, preventing formation of the protective cell wall (Mikusova et al., 1995). A 
summary of the mechanisms of action of these first-line antibiotics is illustrated in Figure 2. 
 
Figure 2: Mechanism of action of first-line anti-TB drugs. Adapted from the CDC. 
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Unfortunately, long-term administration of isoniazid, rifampicin, and pyrazinamide is associated 
with dose-dependent hepatotoxicity. Other serious side effects include peripheral neuropathy 
with isoniazid and optic neuritis with ethambutol (Walker et al., 2011). Nevertheless, these 
drugs are still used as first-line intervention for TB patients due to the lack of safer alternatives 
that results in equivalent efficacy.  
Recommended treatment regimens of TB in adults and children with commercially available 
anti-TB dosage forms are summarized in Table 1. 
Table 1: Conventional Dose Regimens of Anti-TB Drugs 
 
Source: Walker et al., 2011 
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The prolonged duration of treatment, combined with the high probability of drug-induced side 
effects, generally leads to poor adherence of TB-infected patients to these drug regimens. As a 
consequence of premature treatment interruption, chromosomal mutations in M. tuberculosis 
can occur that increase the incidence of drug–resistant tuberculosis (WHO, 2015). 
Drug resistance can be divided into two categories: (1) multiple drug resistance (MDR) and (2) 
extensively–drug resistance (XDR). MDR is caused by bacteria that are resistant to at least 
isoniazid and rifampicin. Clinical cases of MDR are treated with oral and injectable second-line 
anti-TB drugs including aminoglycosides, fluoroquinolones, para-aminosalicylic acid, and 
cycloserine. Treatment must be maintained for at least 24 months, which significantly increases 
the financial burden on patients (Walker et al., 2011). 
XDR, in contrast, refers to resistance against rifampicin, isoniazid, fluoroquinolone, and any of 
the second-line injectable anti-TB drugs, including amikacin and kanamycin. To date, XDR 
infection is considered untreatable using currently available antibiotics (WHO, 2010). However, 
new drug molecules such as SQ-109, PA-824 (nitroimidazoles group), and TMC 207 
(diarylquinolones group) are under development that may offer viable therapeutic options for 
XDR patients in the future (NIH, 2015). 
 
1.2. The Role of AlveolarMacrophages in Pulmonary Immune Defense 
The respiratory epithelium exhibits several defense mechanisms against inhaled foreign 
materials. This includes a highly efficient mucociliary clearance as well as an active immune 
surveillance responding with production of several potent biochemical mediators. If 
microorganisms or foreign particles reach the alveolar space, alveolar macrophages, dendritic 
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cells, monocytes, neutrophils, and lymphocytes will act in concert to initiate an effective 
immune response. Alveolar macrophages (AM) constitute about 90% of the cells recovered in 
bronchoalveolar fluid from healthy individuals. Consequently, it is predicted that these cells 
represent the first-line of defense against the inhaled TB bacteria (Torrelles et al., 2010). 
AMs, originally derived from blood-circulating monocytes, participate in innate immune 
defense by engulfing and digesting microorganisms and cellular debris via phagocytosis 
(Kaufmann, 2000). In addition, AMs contribute to adaptive immune defense activities by 
releasing biochemical signals that stimulate other immune cells such as T-lymphocytes and B-
lymphocytes to take action against the invading pathogens. Several mechanisms are described 
by which AMs can eliminate phagocytosed pathogens. The most prominent mechanism is the 
activation of a biochemical cascade that leads to acidification of the phagosome containing 
engulfed microorganisms (see Figure 3). 
 
 
Figure 3: Biochemical pathway of phagosome acidification in macrophages. (Modified from 
Hackam et al., 1997).  
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After phagocytosis, a pathogen is sequestered within the phagosome, which is an intracellular 
vesicle derived from the plasma membrane. To facilitate enzyme-mediated digestion, the 
phagosome lumen is acidified by the action of cellular enzymes, including the Na+/K+-ATPase, 
vacuolar type H+-ATPases (V-ATPases), and the Na+/H+ exchanger (NHE) (Hackam et al., 
1997). The Na+/K+-ATPase drives an inward Na+ gradient with an outward movement of K+ 
ions from the cell. Since the NHE is usually localized in the cellular membrane of macrophages, 
phagosome formation by invagination of the cell membrane assumes the presence of this critical 
antiporter in the phagosome. The NHE facilitates exchange of one intracellular Na+ ion for one 
extracellular H+ ion, thus, decreasing the pH value of the early phagosomal lumen. The V-
ATPase plays a critical role in acidifying lysosomes. Together with the Na+/K+-ATPase, these 
two enzymes transform early endosomes into acid-carrying vesicles. Lysosomes and acid-
carrying vesicles fuse with the pathogen-containing phagosome, resulting in a highly acidic 
compartment that facilitates effective clearance of engulfed microorganisms via activation of 
different proteolytic enzymes, including hydrolases, superoxide dismutases, and lysozymes 
(Russel et al., 2005). 
In addition, AMs are capable of producing a diverse array of reactive oxygen and nitrogen 
radicals in addition to cytokines such as IL-1β, TNF-α, and IFN-ɣ that are secreted by  
T-lymphocytes. The presence of these biochemical mediators stimulates production of nitric 
oxide from arginine, which reacts with superoxide anions to yield the strongly oxidizing 
peroxynitrite (Yang et al., 2009). Exposure of vesicle-entrapped bacteria to these reactive 
oxygen and nitrogen species denature critical bacterial biomacromolecules such as DNA, lipids 
and proteins, which ultimately leads to elimination of the pathogens. 
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1.2.1. Molecular Aspects of M. tuberculosis Interaction with Alveolar Macrophages 
Earlier studies demonstrated that M. tuberculosis primarily resides in AMs of infected 
individuals (Bermudez et al., 1996). It is hypothesized that TB bacteria enter AMs via receptor-
mediated phagocytosis. In general, AMs can recognize bacteria by two major pathways. First, 
binding of bacterial surface molecules and/or secreted proteins from M. tuberculosis to 
complement receptors that are expressed on the macrophage cell membrane (Schlesinger, 1993). 
Specifically CR1, CR3, and CR4 are predicted to play a major role in this receptor-mediated 
pathway (Russell, 2005). Van Crevel and colleagues reported that TB bacilli entering 
macrophages after CR1 binding have a greater likelihood of survival than those internalized via 
CR3 or CR4 (van Crevel et al., 2002). Alternatively, Fenton and co-workers described 
macrophage phagocytosis facilitated via mannose receptors. According to their findings, 
bacteria internalized via mannose receptors enter with limited ability to fuse with lysosomes 
(Kang et al., 2005). This may explain why some TB strains are considered more virulent when 
entering macrophages via the mannose receptor pathway. 
Since M. tuberculosis has the ability to interfere with different macrophage-specific clearance 
mechanisms, engulfed bacilli may survive inside macrophages for a prolonged time period. 
Cytokines released from CD4+, CD8+ and ɣδ+ T-lymphocytes stimulate infected macrophages, 
which results in formation of granulomatous structures in the lungs. Within those granulomas, 
virulent TB bacilli remain protected from pulmonary clearance mechanisms and adopt for 
intracellular residence within those lesions. This results in TB patients carrying the pathogen 
without developing disease symptoms. In situations where the immune system of such 
individuals is suppressed, M. tuberculosis actively initiates replication inside those granulomas. 
Subsequently, this leads to formation of caeseous detritus, a product of cellular destruction in 
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the center of the granulomatous lesion characterized by a high lipid content. Caeseous detritus 
serves as an important source of nutrients for these bacteria, which further augments bacterial 
replication. Finally, disintegration and liquefaction of this mass can spread pathogenic 
microbes, and as soon as the cavitation approaches the alveoli, patients become infectious 
(Kaufmann, 2000).  
 
1.2.2. Interference of M. tuberculosis with Alveolar Macrophages Clearance  
Various studies identified different mechanisms by which M. tuberculosis can evade 
macrophage-associated clearance mechanism.  
a) Inhibition of phagosome–lysosome fusion 
Phagosome–lysosome fusion is essential for eliminating intracellular pathogens because 
lysosomal proteolytic enzymes and acidic contents are delivered to the phagosomes during this 
process. M. tuberculosis has the ability to prevent phagosome–lysosome fusion by secreting 
sulfatides and polyanionic trehalose glycolipids that are not only components of bacterial 
virulence but also bind to lysosomal membranes rendering them non-fusible (Moulder, 1985). 
Sulfatides and polyanionic trehalose glycolipids secreted by M. tuberculosis are taken up by 
lysosomes, limiting their movement and, hence, reducing the frequency of phagosome-
lysosome collisions. Furthermore, Ferrari and co-workers demonstrated that retention of 
tryptophan aspartate–containing coat (TACO) on phagosomes by living mycobacteria also 
prevents cargo delivery of lysosomes to the pathogen-containing phagosomes. TACO is a 
protein present on the surface of phagosomes-containing viable mycobacteria. This protein is 
usually released before phagosomal fusion with lysosomes. In TACO-deprived macrophages, 
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mycobacteria were readily transported to lysosomes followed by effective degradation. The 
presence of TACO in mycobacteria-infected macrophages prevented delivery of lysosomes and, 
consequently, prolonged intracellular survival of the pathogen (Ferrari et al., 1999). 
b) Inhibition of phagosomal acidification 
Mycobacteria synthesize protein tyrosine phosphatase A (PtpA) that enables exclusion of the  
V-ATPase in phagosomes (see Figure 3, Wong et al., 2011). Upon internalization of  
M. tuberculosis, secreted PtpA will dephosphorylate and eventually inactivate VPS33B, a 
macrophage regulatory membrane protein that is necessary for phagosome-lysosome fusion. 
This will prevent transfer of the V-ATPase to phagosomes. As a result, the lumen of 
Mycobacteria-containing phagosome is less acidic (i.e., pH value around 6.2 instead of pH 4.7-
5.5) limiting effective pathogen clearance by the acid-dependent enzymes. (Sturgill-Koszycki et 
al., 1993). 
c) Protection against oxidative radicals 
M. tuberculosis can secrete enzymes capable of inactivating free radicals that are produced by 
macrophages to oxidize invading pathogens. This includes enzymes such as the alkyl 
hydroperoxide reductase subunit C, which facilitates neutralization of peroxynitrite (Bryk et al., 
2002) and the methionine sulfoxide reductase, which dissociates peroxynitrite-modified 
methionine residues (St John et al., 2001). In addition, Yuan and co-workers described earlier 
that M. tuberculosis has the ability to chemically modify its mycolic acids by cyclopropanation. 
As a consequence of this cis-cyclopropane modification, these slow-growing bacteria will be 
protected from oxidative stress (Yuan et al., 1995). 
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In summary, M. tuberculosis creates a “safe” environment inside AMs mainly by manipulating 
biochemical mechanisms essential for acidification of pathogen–containing phagosomes. This 
unique feature of TB-infected macrophages constitutes the scientific basis for designing 
selective drug delivery systems intended to preferential release of a therapeutic payload in TB-
infected macrophages. 
 
1.3. Drug Delivery Technology to Manage Tuberculosis  
1.3.1. Conventional Drug Delivery Systems used in TB  
To date, commercially available delivery systems of anti-TB agents are limited to oral and 
parenteral routes of administration using compressed tablets, capsules, or solutions. As a 
consequence, drug distribution is non-specific leading to sever side effects. Combined with the 
prolonged duration of treatment that is required for achieving a sustained therapeutic response 
in infected individuals, a significant fraction of TB patients on conventional drug regimens 
becomes non-compliant, which aids in the development of MDR. As parenteral administration 
of anti-TB formulations causes pain and discomfort, it is not considered a viable alternative for 
long-term therapy of TB (Du Toit et al., 2006). Furthermore, unfavorable pharmacokinetic 
properties of anti-TB drugs taken orally that result in highly variable plasma concentrations 
negatively affect patient compliance. Hereditary differences in acetylation status increase the 
risk of hepatotoxicity for slow acetylators who are taking INH orally (Huang et al., 2002). 
Long-term administration of rifampicin has been demonstrated to induce expression of 
cytochrome P450 metabolizing enzymes, which can decrease oral bioavailability of 
concomitantly administered drugs (Baciewicz et al., 1984). To overcome the predicament of 
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poor patient compliance associated with conventional drug delivery systems of anti-TB drugs 
that increases the risk of MDR, alternate routes of administration as well as improved drug 
delivery technologies that can achieve selective targeting of TB-infected AMs must be explored. 
 
 
1.3.2. SMART Drug Delivery Systems  
Utilization of pharmaceutically acceptable excipients that can alter physicochemical properties 
in response to external or internal stimuli offers a novel avenue in drug delivery to overcome 
significant limitations associated with conventional dosage forms. For TB patients, 
nonadherence to long-term treatment and poor clinical outcome can be improved by reducing 
the dose frequency using sustained or controlled drug delivery systems. Selective targeting of 
TB-infected tissues, specifically pulmonary AMs, will further increase patient compliance due 
to anticipated reduction in drug-induced side effects (Bullo et al., 2012). Consequently, this 
research attempts to create Systems to Maximize Access, Retention, and Therapy or Systems to 
Mute until Activation by a Remote Trigger (SMART) drug delivery systems for TB patients 
that can be administered via inhalation for selective targeting of pulmonary AMs. 
Historically, various polymers have been designed that change their physicochemical properties 
in response to different stimuli (Bennet et al., 2014). These stimuli are summarized in Table 2. 
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Table 2: Overview of Stimuli-Induced SMART Drug Delivery Systems. 
Stimulus Example Reference 
Chemical 
pH Foss et al., 2004 
Gases (hypoxia) Thambi et al., 2014 
Redox reactions Meng et al., 2009 
Biochemical 
Enzymes De La Rica et al., 2012 
Hormones Chung et al., 2013 
Physical 
Electric field Kwon et al., 1991 
Magnetic field Allam et al., 2013 
Optical (laser) Xiong et al., 2013 
Multi-stimuli Temperatue/pH/redox Klaikherd et al., 2009 
 
In cancer therapy, for example, thermosensitive polymers allow fabrication of stimulus-
responsive drug delivery systems where drug release is facilitated by gel-sol transition at a 
critical solution temperature (Abulateefeh et al., 2011). Since the tumor microenvironment is 
approximately 1–2°C warmer than normal healthy tissue (Vaupel et al., 1989), thermos-
responsive polymers preferentially dissolve and release the drug at the tumor site sparing 
healthy tissue from drug exposure, which effectively reduces side effects (Rejinold et al., 2011).  
For oral drug delivery, pH-responsive polymers have been used for decades to prevent 
premature drug release under acidic conditions of the stomach (Foss et al., 2004). Suitable  
pH-responsive polymers contain ionizable groups attached to the backbone of the molecule. In 
response to changes in environmental pH, the coiled polymer chains expand due to electrostatic 
repulsion from the charges generated by ionization. This conformational change triggers release 
of encapsulated payload in response to an external pH stimulus. 
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Polymerization products of acrylic or methacrylic acid, including corresponding esters such as 
EudragitTM are examples of pH-responsive polymers which have been widely used by 
pharmaceutical industry to prepare enteric coated and/or controlled release drug delivery 
systems (Evonik, 2015). Selection of defined functional groups in the side chain of this polymer 
allows precise tuning of release properties under desired pH conditions. Different pH-dependent 
dissolution profiles of commercially available EudragitTM polymers are summarized in Figure 4. 
 
Figure 4: pH-dependent dissolution rates of Eudragit polymers. (Source: http://eudragit.evonik.com) 
 
Khan and co-workers used Eudragit L100 and Eudragit S100 to coat mesalazine tablets for  
pH-dependent colon-targeted oral drug delivery (Khan et al., 2000). Eudragit L-100 
preferentially dissolves at pH values greater than pH 6.0, while Eudragit S-100 only starts to 
dissolve at pH >7.0. The results from this study demonstrate that these two polymers can be 
used to prepare oral formulations capable of selectively releasing mesalazine at any desirable 
region of the intestine in response to luminal pH between 6.0 and 7.0. 
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Colloidal particles with diameter of less than one micrometer have been utilized as efficient 
delivery tools for therapeutic molecules (NIH, 2012). These nanoparticles (NPs) can be 
fabricated using a diverse array of materials isolated from natural sources such as alginate, 
chitosan, and albumin or prepared by chemical synthesis, including polyacrylamides, 
polycaprolactones, poly lactide-co-glycolide, or solid lipids (Gelperina et al., 2005). 
Depending on the matrix composition and fabrication design, NPs can be categorized into (1) 
monolithic nanoparticles (or nanospheres) in which the payload is dispersed in the polymeric 
matrix and (2) nanocapsules in which the payload is confined within a hydrophobic or 
hydrophilic core surrounded by a shell-like membrane (Kreuter 2004).  
NP represents a versatile drug delivery platform for incorporation of hydrophobic and 
hydrophilic substances that may enhance the stability of these payloads. In addition, NPs offer 
high encapsulation capacity and can be administered by various routes of administration 
(Gelperina et al., 2005). Most relevant to this research, NPs have been demonstrated to 
accumulate in AMs, the reservoir for M. tuberculosis bacilli (Gupta et al., 2012). Anisimova 
and co-workers explored encapsulation of isoniazid and streptomycin into poly (butyl 
cyanoacrylate) NPs. Intracellular accumulation of both drugs encapsulated in NPs was greater 
in human blood monocytes when compared to non-encapsulated drugs formulations and 
resulted in significantly improved antimicrobial activity against M. tuberculosis inside human 
monocytes-derived macrophages (Anisimova et al., 2000). Similarly, Fawaz and colleagues 
demonstrated improved pharmacological activity of intravenous ciprofloxacin encapsulated in 
poly (isobutylcyanoacrylate) NPs against TB bacteria inside infected macrophages when 
compared to an equivalent intravenous drug dose (Fawaz et al., 1998).  
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NPs specifically offer promising opportunities for pulmonary administration of anti-TB drugs. 
In addition to preferential uptake by AMs, inhaled drug-loaded NPs bypass extensive hepatic 
first-pass metabolism, and consequently, minimize serious adverse effects associated with anti-
TB drug regimens (Bullo et al., 2012). Pandey and co-workers investigated the effect of a single 
dose of (poly lactide-co-glycolide)-encapsulated isoniazid, rifampicin, and pyrazinamide NPs 
administered in guinea pigs by nebulization (Pandey et al., 2003). Sustained therapeutic drug 
levels were measured in the lungs for up to 11 days. Subsequent administration of these 
nebulized NPs once every 10 days (total 5 doses) to TB–infected guinea pigs resulted in 
eradication of the bacilli in the lung. In comparison, 46 daily oral doses were required to obtain 
an equivalent therapeutic effect.  
As particle size critically determines tissue distribution after inhalation (Labiris et al., 2003), the 
objective of this research project was to fabricate NPs with a defined diameter of approximately 
250 nm. Inhaled particles larger than 10 μm are deposited in the oropharyngeal zone by inertial 
impaction. These large particles can contribute to a desired therapeutic response but only after 
absorption from the gastrointestinal tract. To expose AMs to drug-loaded NPs, gravitational 
sedimentation laws require particle diameter <500 nm. According to Labiris and co-workers, 
particles with diameter of approximately 250 nm exhibit a longer residence time in the alveolar 
region, which is predicted to allow sufficient time for resident AMs to internalize this drug-
containing SMART drug delivery system. 
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2. Research Objective 
2.1. Hypothesis 
Nanoparticles fabricated from acrylic polymers facilitate stimulus-induced payload release 
under pH conditions present in M. tuberculosis-infected macrophages. 
2.2. Specific Aims 
To explore this hypothesis experimentally, we propose the following specific aims: 
 Specific Aim 1 
To fabricate Eudragit L-100 NPs of approximately 250 nm in diameter and explore in 
vitro payload release at pH 5.5, 6.2, and 7.4. 
 Specific Aim 2 
To assess cellular internalization efficiency and pH-dependent payload release from the 
Eudragit L-100 NPs in control and pH-modified macrophages. 
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3. Materials and Methods 
3.1. Materials 
Eudragit® L-100 molecular weight (M.W.) = 125,000 was a gift from Evonik Industries AG 
(Darmstadt, Germany). Fluorescin isothiocyanate-labelled dextran, M.W. = 40,000 (FD40) was 
purchased from Sigma-Aldrich (St. Louis, MO). Rhodamine123 UltraPure grade (M.W. = 380) 
was supplied by Anaspec Inc. (Fremont, CA). Pierce BCA Protein Assay kit was obtained from 
Thermo Fisher Scientific Inc. (Pittsburgh, PA). CellTiter-Glo® Luminescent Cell Viability 
Assay kit was obtained from Promega Corporation (Madison, WI). RIPA Lysis Buffer was 
purchased from Santa Cruz Biotechnology (Dallas, TX). Spectra/Por 3 dialysis membrane with 
M.W. cut-off = 3.5 kDa was purchased from Spectrum® Laboratories, Inc. (Rancho 
Dominguez, CA). All other chemical reagents were of high purity or analytical grade. 
 
3.2. Cell Culture 
The MH-S mouse alveolar macrophages cell line CRL-2019 was purchased from American 
Type Culture Collection (Rockville, MD). Cells were routinely maintained in phenol red-free 
Dulbecco’s modified Eagle medium (DMEM) from Corning Cellgro (Manassas, VA) 
supplemented with L-glutamine 2% (v/v), non-essential amino acids 1% (v/v), 
penicillin/streptomycin (10,000 I.U./mL each), 2-mercaptoethanol 0.00035% (v/v), and heat-
inactivated fetal bovine serum 10% (v/v) at controlled incubation conditions of 37°C, 5% CO2 
and 90% relative humidity. 
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3.3. Fabrication of Eudragit L-100 Nanoparticles 
Nanoparticles were prepared by the nanoprecipitation method adapted from Bharathi and 
colleagues, 2012. Briefly, a stock solution of rhodamine123 (Rh123) was prepared in dimethyl 
sulfoxide (DMSO) (1.9 mg/mL) by dissolving 9.5 mg Rh123 in 5 mL of DMSO. A standard 
batch of a nanoparticle suspension was prepared by combining 42 μL of the Rh123 stock 
solution in DMSO with 10 mL of acetone/water (97:3, v/v). Subsequently, 100 mg of Eudragit 
L-100 was added gradually over 5 minutes with frequent shaking of the organic solvent until the 
polymer dissolved and no solid particles residues were visible. Using a Pasteur pipet, this 
organic phase was added drop by drop over 3 minutes into 20 mL of deionized distilled water 
(ddH2O) under magnetic stirring (600 rpm). This mixture was left under stirring in fume hood 
for 3 hours until complete evaporation of acetone was confirmed gravimetrically. At the end, 
this suspension of nanoparticles was purified by centrifugation for 30 minutes at 3,900 x g using 
a Marathon 21000R centrifuge (IEC, Needham Heights, MA). Twenty (20) mL of the 
supernatant was collected and then subjected to dialysis against 2 L of 0.3 μM HCl (pH = 3.5)  
using a dialysis bag under magnetic stirring at 100 rpm for 2 hours in order to eliminate the 
fluorescent dye adsorbed on the surface of Rh123-containing NPs. The dialysate was replaced 
with fresh HCl solution after two hours, and the dialysis continued overnight. The NP 
suspension was stored at room temperature in a dark place until further use.  
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3.4. Physical Properties of the Nanoparticles 
Particle size distribution and zeta potential of the fabricated NP were measured by dynamic 
laser light scattering using the Zetasizer Nano-ZS (Malvern Instruments, Worcestershire, U.K.) 
according to the manufacturer’s instructions. All the values of particle size reported in this 
project refer to the equivalent hydrodynamic diameter.  
For NP size measurement, 1 mL of the aqueous NP suspension was loaded into a disposable 
micro- cuvette, and placed inside the device. After a 2-minute equilibrium at 25°C, laser scatter 
was acquired at 173° Backscatter detection. Measurements of the same sample were repeated 
three times, and the average and standard deviation were calculated. For the zeta potential 
measurement, a disposable capillary cell was used, and then placed inside the machine at 25°C 
and equilibrated of 2 minutes. 
 
3.5. Rhodamine123 Encapsulation Efficiency  
To determine the encapsulation efficiency of Rh123 in Eudragit L-100 nanoparticles, 2 mL of 
the nanoparticle suspension was loaded into a Spectra/Por 3 tubing (M.W. cut-off = 3.5 kDa) 
that was pre-equilibrated in ddH2O for at least 15 minutes. Polymeric nanoparticles were 
dissolved by exposure to 18 mL of 0.5 M NaOH under magnetic stirring (100 rpm) for 4 hours 
at room temperature.  
0.2 mL of the polymer-free dialysate was removed for spectrophotometric fluorescence analysis 
at EM = 520 nm, EX = 485 nm (Polarstar Optima, BMG Labtech, Ortenberg, Germany), and 
Rh123 concentration was quantified using a calibration curve of Rh123 in NaOH. 
Encapsulation efficiency (E.E.) was calculated in percent using the following equation: 
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 .  . % =
  
  
∗  100 %                   (Eq. 1) 
Where Q∞ = amount of encapsulated Rhodamine123 that was released from NPs into NaOH 
dialysate, Mt   = initial amount of Rh123 used in NPs fabrication. 
The amount of Eudragit L-100 that was recovered in the fabricated nanoparticles was quantified 
gravimetrically. Briefly, 2 mL of nanoparticles suspension was transferred into aluminum weigh 
dish, and left for drying at room temperature. Samples weights were recorded using XS205 
DualRange Analytical Balance (Mettler-Toledo LLC, Columbus, OH) at different time points 
and complete evaporation of the suspension was obtained after 24 hours. Rh123 loading 
capacity (L.C.) of the Eudragit L-100 nanoparticles was calculated according to the following 
equation: 
 .  . =  
  
 
                    (Eq. 2) 
Where Q∞ = amount of encapsulated Rhodamine123 that was released from NPs into NaOH 
dialysate, P = the amount of Eudragit L-100 incorporated in the purified nanoparticles.  
 
3.6. Rh123 Release Kinetics In vitro  
Time-dependent release of Rh123 from Eudragit L-100 NPs was assessed at pH 5.5, 6.2, and 
7.4 using phosphate buffer solutions. Five mL of the Rh123-nanoparticle suspension were 
loaded into hydrated Spectra/Por 3 dialysis tubes, which were placed into a 100 mL glass beaker 
containing 75 mL of phosphate buffer, adjusted to the desired pH value. Rh123 release 
experiments were performed at room temperature under magnetic stirring at 300 rpm. At 
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specific time points, 200 μL aliquots were removed from the dialysate, and Rh123 was 
quantified fluorometrically using Polarstar Optima (BMG Labtech, Ortenberg, Germany). Fresh 
buffer solution was used to replace the volumes removed in order to maintain sink condition. 
Fluorescence readings were converted to Rh123 concentrations using standard curve data of 
Rh123 in phosphate buffer of the corresponding pH value, and the cumulative amount of Rh123 
released at each time point was calculated using the following equation: 
   =    .     +      .    
   
    
                         (Eq. 3) 
Where Qn = the cumulative amounts of Rh123 released at sampling interval n, Cn = 
concentration of Rh123 determined at nth sampling interval, Vt  = Volume of the dialysis 
medium = 75 mL, Ci = Rh123 concentration determined at each sampling interval, Vs  = sample 
volume removed = 0.2 mL. 
These values were subsequently divided by the total amount of the dye that was encapsulated in 
the nanoparticles to express cumulative release kinetics of rhodamine123 in percent: 
   % =
  
  
∗  100 %                                  (Eq. 4) 
Where Rn = cumulative Rh123 release at sampling interval n, Qn = the cumulative amounts of 
Rh123 released at sampling interval n, Q∞   = amount of encapsulated Rhodamine123 in the NP 
batch. 
In an attempt to delineate the release mechanism of Rh 123 from nanoparticles, the pH–
dependent release data were fitted to various mathematical model previously reported. The 
release data was linearized according to the literature, and linear regression analysis was 
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performed. Goodness of fit was assessed based on the value of correlation coefficient (R2) and 
randomness of residuals. 
a) Zero-order model 
This model describes passive diffusion in systems where the rate of drug release is independent 
of its concentration. Mathematically, the release profile follows: 
Qt = Q0 + K0 t             (Eq. 5) 
where Qt  = cumulative amount of Rh123 released in time t, Q0 = the initial amount of drug in 
the solution (in most cases, Q0  = zero), and K0  = the zero order release constant expressed in 
units of concentration/time.  
To study the release mechanism, data obtained from in vitro release studies were plotted as Qt 
versus time.  
 
b) First-order model: 
In this model, the drug release rate depends on its concentration in the dosage form. It can be 
expressed by the equation: 
Qt = Q0 * e ‐ k t      (Eq. 6) 
where Qt  and Q0 as mentioned above, k = first order rate constant, and t = time. In vitro release 
data obtained were linearized by plotting log cumulative percentage of Rh123 remaining against 
time. 
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c) Higuchi model: 
This model explains the release of drugs incorporated in semi-solid and/or solid matrices by 
diffusion. It can be expressed by: 
   =        (2  −    )                 ( Eq. 7) 
In which Qt  = the cumulative amounts of Rh123 released in time t per unit area A, C = the drug 
initial concentration, Cs = drug solubility in the matrix media, and D = the diffusion coefficient 
of the drug. In vitro release data can be plotted as Qt versus square root of time (Silvina et al., 
2002). 
 
d) Hixson-Crowell model 
This model describes drug release by dissolution from systems where a change in surface area 
and diameter of the particles is present. Hixson and Crowell found that the particles’ regular 
area is proportional to the cube root of its volume. They derived the following equation: 
 
  
   / 
−     
   / 
  = κ*t         (Eq. 8) 
Q∞  = amount of drug in the dosage form, Qt  = cumulative amounts of Rh123 released in time t, 
and κ = a constant incorporating the surface-volume relation. Data obtained from in vitro 
release studies can be plotted as cube root of Qt   against time (Hixon et al., 1931). 
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e) Baker-Lonsdale model 
This model describes the release of drugs from spherical matrices, in which the release 
mechanism is a combination of polymer erosion and diffusion: 
 
 
∗   1 −  1 −  
  
  
 
 
 
  −  
  
  
=                (Eq. 9) 
Qt/Q∞ = fraction of drug released at time t, kb = Baker-Lonsdale release rate constant. In vitro 
release data was plotted as [d (Qt/Q∞)]/dt against the root of time inverse (Baker et al., 1974). 
 
f) Korsmeyer-Peppas model 
Korsmeyer and Peppas derived an equation that attributed drug release to dynamic swelling and 
dissolution of the polymer: 
  
  
=                         (Eq. 10) 
Where a = constant incorporating structural and geometric characteristics of the drug dosage 
form, n = the release exponent, t = time. In vitro release data were plotted as log Qt versus             
log time (Korsmeyer et al., 1983). 
 
3.7. Cells Viability  
MH-S macrophages were seeded in 96-well plate at density of 50,000 cells/well and incubated 
in 200 μL serum-containing DMEM for 48 hour at 5% CO2 (v/v), 37° C. Then, culture medium 
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was removed by aspiration, and cells washed twice with pre-warmed phosphate buffer saline pH 
7.4 (PBS). 100 μL of NPs equivalent to a polymer concentrations range from 0.93 to 4.65 
mg/mL were added to the cells and incubated at 37° C for up to 6 hours. At the end of each 
incubation period, NP suspension was removed by aspiration and cells were washed once with 
ice-cold PBS. Thereafter, 100 μL serum-containing DMEM was added to each well and 
incubated overnight at 5% CO2 (v/v), 37° C. The next day, 100 μL/well of the CellTiter Glo 
reagent was added, and the plate was mixed for 2 minutes using an orbital shaker. After a rest 
for 10 minutes at room temperature, luminescence was quantified using the Polarstar Optima 
microplate reader. The cells that were exposed to different concentrations of Eudragit L-100 
gave luminescence readings that were normalized to those of the cells that were incubated with 
the negative control (serum-free DMEM) to estimate the percentage of cell viability. RIPA 
buffer (30 μL/well) which resulted in complete cellular lysis was considered as positive control. 
Results were fitted to the sigmoidal dose-response Eq. 11 using GraphPad Prism 5.0 
Cell viability=
100
1 + 10(          ) .           
             (Eq. 11)      
where x = polymer concentration (mg/mL), IC50 = polymer concentration that compromise the 
growth of 50 % of the cells. HillSlope describes the steepness of the curve.  
 
3.8. Cellular Uptake Studies 
MH-S cells were seeded in 96-well transparent plate at a density of 50,000 cells/well and 
incubated for 48 hours in serum-containing phenol red-free DMEM. Prior to uptake 
experiments, cells were washed twice with 200 μL of PBS at room temperature and 200 μL/well 
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of the nanoparticle suspension was added. Control experiments were performed with equivalent 
concentration of Rh123 solution in the same medium. The cells were incubated for 30 minutes 
in the incubator under 5% (v/v) CO2, 37°C. After that, the treatment was removed by aspiration 
and cells washed twice using ice-cold PBS. Then, 200 μL/well PBS was added, and the samples 
were taken for fluorescence analysis. PBS was removed from cells, and 200 μL/well RIPA lysis 
buffer was added. The fluorescence was measured after 1, 3, 6, and 18 hours of RIPA addition 
using a spectrophotometer. 
 
3.9. BCA Cellular Protein Quantification Assay 
Protein concentrations were determined using the BCA Protein Assay kit, which was prepared 
following the manufacturer’s protocol. MH-S mouse alveolar macrophages were seeded in 
DMEM into transparent 96-well plate at a density of 10,000, 25,000, and 50,000 cells/well, and 
were divided into two groups: the control in which the cells were not subjected to washing or 
other manipulation steps; and the second group of cells that were subjected to these 
manipulations. Both groups were incubated for different periods (overnight, 24 hours, and 48 
hours). At the end of each incubation period, DMEM was removed from cells of the second 
group, and 100 μL/well of serum-free DMEM was added. The plate was incubated for an 
additional 4 hours. After that, serum-free medium was removed, and the cells were washed 
three times with ice-cold PBS. 100 μL/well of DMEM medium was added, and the plate was 
incubated overnight at 5% CO2 (v/v), 37°C. The next day, DMEM medium was removed from 
both groups, and 30 μL/well of RIPA lysis buffer was added. The plate was incubated for 30 
minutes. 
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Next, 250 μL/well of BCA reagent was added to all cells, and the plate was incubated in a water 
bath at 37° C for 30 minutes to stabilize the signal. Absorbance was measured at λ = 570 nm 
using SpectraMax Plus 384 microplate reader (Molecular Devices LLC., Sunnyvale, CA), and 
absorbance values were converted to protein concentrations using a calibration curve prepared 
with bovine serum albumin standards ranging from 0 – 16 μg/mL. 
 
3.10. Lysosomal pH  
FD40 was used to measure the pH of cellular lysosomes as was adopted by Ohkuma et al. 
(1978) and Geisow et al. (1981). 
Aliquots of 1 μg/mL of FD40 in PBS of different pH values (3.5 – 8.5) were prepared. The 
fluorescence was recorded at 520 nm emission wavelength after using 485 nm and then 460 nm 
excitation wavelengths. The fluorescence ratio at each pH value was calculated, and a 
calibration curve was constructed. 
MH-S cells were seeded in 96-well plate at density of 5x104 cells/well, and incubated in                
100 μL/well of serum-containing DMEM for 24 hours at 5% CO2 (v/v), 37° C. The next day, 
100 μL/well of FD40 (concentrations equal to 0.5, 1 or 2 mg/mL in serum–free DMEM) was 
added, and the cells were incubated again for different periods (up to 24 hours). At the end of 
each period, 30 μL/well of Trypan blue (1.2 mg/mL) was added to each well. Then, FD40 
fluorescence was measured at specific time intervals using excitation wavelength at 485 nm and 
460 nm, and emission of 520 nm. 
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 3.11. Simulated Lysosomal Conditions of TB-infected Alveolar Macrophages 
Cells were seeded in 96 well plate at density (5x104 cells/well) and incubated for 48 hours at 5% 
CO2 (v/v), 37° C. At the end of 48 hours, 40 μL of FD40/PBS (concentration 2.5 mg/mL) was 
added to each well, and the cells were incubated for 3 hours. At the end of 3 hour, cell medium 
and FD40/PBS mixture were removed, and cells were washed twice with ice-cold PBS. Then, 
200 μL of either NH4Cl (ranging from 0.1 – 1 mM) in amino acid-free DMEM medium 
(Treated cells) or the Control cells (given only amino acid-free DMEM medium) was added to 
each well, and the plate was incubated for 1 hour. After that, these solutions were removed, and 
200 μL/well of either Rh123-loaded NPs (polymer concentration equals to 1.62 mg/mL) or the 
equivalent concentration of Rh123 solution in phenol red-free SFM was added to cells, and 
incubated for 30 minutes. The Rh123-loaded NP and Rh123 solution were removed, and cells 
were washed twice with ice-cold PBS. Then, 200 μL/well of PBS was added, and the samples 
were taken for fluorescence and confocal microscope (Zeiss LSM510 META) measurements. 
PBS was removed from cells, and 200 μL/well of RIPA lysis buffer was added to them. The 
fluorescence was measured after 1, 3, 6, and 18 hours of RIPA addition using 
spectrophotometer. 
 
3.12. Confocal Microscope 
The uptake of Rh123-NPs and Rh123 solution was determined by visualizing the green 
fluorescence inside MH-S cells using the Zeiss LSM510 Confocal Microscope (Zeiss, 
Germany). The LSM 510 consists of a Zeiss Axiovert 200M microscope Meta detector head 
(range 410-750 nm). For green fluorescence, Argon Laser was used (EX = 488 nm and EM 505-
530 nm). MH-S cells were seeded in culturewell 16-chambered coverglass (Grace Bio-Labs, 
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Bend, OR). DMEM was removed from cells and PBS added prior to confocal microscope 
analysis. 
 
3.13. Statistical Analysis 
The experiments were conducted in triplicate unless otherwise stated. All results are represented 
in mean ± standard deviation (SD). Statistical differences between groups were assessed for 
significance by GraphPad Prism 5.0 (GraphPad Software, Inc., La Jolla, CA) using analysis of 
variance (ANOVA) or Student’s t-test. Microsoft Office Excel 2013 was used for regression 
analysis of in vitro release studies. 
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4. Results 
4.1. Eudragit L-100 Nanoparticles 
4.1.1. Physicochemical Properties of Eudragit L-100 Nanoparticles 
The main objective of the NP fabrication process was to obtain colloids with an average 
diameter of approximately 250 nm to facilitate efficient phagocytosis by the AMs. As described 
by Devarajan and co-workers, factors such as polymer feed and stirring time most dramatically 
affect nanoparticle size (Devarajan et al., 2007). 
 
Figure 5: Optimization of NP size. Effects of magnetic stirring duration and Eudragit L-100 feed 
were varied during fabrication process. Mean hydrodynamic particle diameter of colloid dispersion in 
water was measured by DLS. Results are shown as mean ± SD (n = 3). 
 
The results summarized in Figure 5 demonstrated that the particle size increased with increasing 
polymer feed up to 100 mg of Eudragit L-100. Interestingly, stirring times between 1-3 hours 
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after addition of the polymer solution did not affect mean particle size if polymer feed was kept 
constant (p = 0.71 in 25 mg polymer feed; p = 0.12 in 50 mg polymer feed; and p = 0.6 for  
100 mg polymer feed). Based on these results, 100 mg of Eudragit L-100 in combination with  
a 3 hours magnetic stirring period were selected for standard NP batch fabrication. The longer 
stirring time assured quantitative evaporation of acetone, which was used to dissolve the 
polymer. Eudragit L-100 nanoparticles prepared by this optimized nanoprecipitation technique 
exhibited a mean particle diameter of 270 ± 17 nm and a zeta potential of -21.8 ± 1.4 mV (n = 3 
batches). 
4.1.2. Rhodamine123 Encapsulation Efficiency 
Quantifying the NP encapsulation efficiency for the drug surrogate Rh123 is essential to 
determine the payload capacity that is carried by these NPs and, subsequently delivered to the 
lysosomes of TB-infected AMs. Analytically, this is accomplished by complete dissolution of 
Rh123-containig NPs using an appropriate solvent followed by spectrophotometric 
determination of the total Rh123 concentration in solution. In an effort to achieve complete NP 
dissolution with a limited time frame, the effect of multiple mixing techniques, including high-
shear mixing, ultrasonication, and magnetic stirring, on the size distribution of Eudragit L-100 
NPs was tested. Magnetic stirring for up to 2 hours did not significantly reduce the fraction of 
particles ≥1 μm, which were assumed to represent aggregates of fabricated NPs. High-shear 
mixing, in contrast, appeared to increase aggregations of NPs resulting in a greater fraction of 
particles with a diameter ≥1 μm (see Figure 6). Similarly, ultrasonication resulted in the 
formation of very large aggregates (data are not shown).  
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Figure 6: Effect of different mixing techniques on NP size distribution. Eudragit L-100 
particle size distribution was measured by DLS after dispersion of NPs in acetone/water (97:3, v/v). 
Control experiments were performed with Eudragit L-100 NP under similar conditions but without 
application of any physical mixing. Results are shown as mean ± SD (n = 3). 
  
From these data, it was concluded that exposure of NPs in acetone/water to greater physical 
forces favors particles aggregation rather than dissolution. Therefore, different solvent systems, 
including 100% (v/v) of isopropanol, ethanol and acetone, were explored using magnetic 
stirring. Consistently, particle size measurements revealed again the presence of a significant 
fraction of Eudragit L-100 NPs with a diameter ≥1 μm when compared to control polymer 
dissolved in acetone/water (Figure 7). 
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Figure 7: Effect of different solvents on NP size distribution. Eudragit L-100 NP suspension 
prepared in indicated solvents and incubated for 10 minutes or 24 hours under consistent magnetic 
stirring. Control experiments were performed using Eudragit L-100 polymer in acetone/water (97:3, 
v/v). Particle size distribution was measured by DLS.  
 
The results from experiments performed with these organic solvents did not suggest sufficient 
success in dissolving the NPs, which is a prerequisite for accurate determination of the 
encapsulation efficiency. As an alternative option, sodium hydroxide solutions were 
investigated, which can chemically hydrolyze the ester bonds between copolymer chains 
(Evonik 2015).  
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Figure 8: Effect of sodium hydroxide on Eudragit L-100 NP particle size distribution. 
NPs were incubated for 10 minutes or 24 hours with aqueous NaOH solutions under magnetic 
stirring. Control experiments were performed using Eudragit L-100 polymer in acetone/water (97:3, 
v/v). Particle size distribution was measured by DLS.  
 
Short-term incubation of Eudragit L-100 NPs in NaOH solutions ranging from 0.5-5 M 
consistently eliminated the fraction of aggregates ≥ 1 μm (see Figure 8). To limit possible 
chemical degradation of encapsulated Rh123, a 10-minute incubation of NPs in 0.5 M NaOH 
was selected for quantitative assessment of Rh123 encapsulation efficiency. 
Since Eudragit L-100 was interfering in the spectrophotometric quantification of Rh123 (data 
not shown), it was necessary to separate this polymer from Rh123 by dialysis. To determine the 
time required for complete dissolution of Rh123-containing Eudragit L-100 NPs in 0.5 M 
NaOH and subsequent diffusion of released Rh123 across the 3.5 kDa dialysis membrane, 
dialysate samples were removed at different time points and quantified for Rh123 using 
fluorescence spectrophotometry. The kinetics profile of Rh123 in the dialysate is shown in 
Figure 9. 
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     Figure 9: Dissolution of Rh123-containing Eudragit L-100 NPs kinetics. NPs 
suspension was incubated in 0.5 M NaOH inside a 3.5 kDa dialysis bag, and dialysate was 
quantified spectrofluorometrically for Rh123 using EX = 485 nm and EM = 520 nm. Results are 
shown as mean ± SD. (n = 3). 
 
Within the first few hours, increasing Rh123 concentrations were measured in the dialysate. 
However, the appearance rate of this fluorescent probe in the dialysate significantly decreased 
after 2 hours reaching equilibrium after approximately 4 hours. The results from this experiment 
implied that complete dissolution of the Rh13-containing Eudragit L-100 NP in 0.5 M NaOH 
and subsequent diffusion of the fluorescent probe across the dialysis membrane was completed 
after approximately 4 hours. Consequently, this time point was considered appropriate to 
determine encapsulation efficiency of Rh123 in Eudragit L-100 NPs.  
Using six different NP batches, the mean encapsulation efficiency of Rh123 was 74 ± 2 % 
(w/w). To estimate the corresponding loading efficiency, the polymer amount recovered after 
NP purification was determined gravimetrically (= 93 % of initial Eudragit feed). Accordingly, 
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the loading capacity of Rh123 in the fabricated NPs was calculated as 0.63 ± 0.02 mg 
Rh123/mg Eudragit L-100. 
To explain the effect of Rh123 incorporation and subsequent dialysis of Rh123-containing NPs 
on physicochemical properties of fabricated NPs, mean particle size and zeta potential were 
compared with Eudragit L-100 alone. 
 
Table 3: Physical Characteristics of Eudragit L-100 Nanoparticles 
 
Blank Eudragit L-
100 NP 
(n = 3) 
Rh123-loaded NP 
  (no dialysis) 
(n = 6) 
Rh123-loaded 
NPs  (dialyzed) 
(n = 3) 
 
Nanoparticles 
diameter [nm] 
 
270 ± 17 276 ± 30 238 ± 22 
Zeta potential [mV] -21.8 ± 1.4 - 25.0 ± 3.0 - 33.1 ± 7.1 
 
            * Values represent mean ± SD.  
 
As shown in Table 3, it appears that neither incorporation of Rh123 nor the use of dialysis to 
remove particle-adsorbed Rh123 significantly alter relevant particles properties that govern 
colloidal stability and cellular uptake.  
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4.1.3. Release Kinetics of Rh123 from Eudragit L-100 NP 
The aim of this experiment was to measure the release of Rh123 from Eudragit L-100 NPs 
under pH conditions present in the lysosome of TB-infected phagosomes, control non-infected 
AMs, as well as the bronchial lumen where NPs were expected to be deposited after pulmonary 
administration. The cumulative release profiles of Rh123 from Eudragit L-100 NPs at pH 5.5, 
6.2, and 7.4 were measured in vitro at 25°C using PBS. 
 
 
Figure 10: pH-dependent release of Rh123 from Eudragit L-100 NPs. Rh123-containing NPs 
were incubated at room temperature in PBS pH 5.5, 6.2 and 7.4. Samples were removed at different time 
points and Rh123 concentration was quantified spectrofluorometrically (EX = 485 nm, EM = 520 nm). 
Results are shown as mean ± SD. (n = 3). 
 
The cumulative Rh123 profiles shown in Figure 10 underline a pH-dependent release process 
that can be attributed to the hydrolysis in the ester backbone of the Eudragit L-100 co-polymer. 
The total cumulative dye release from the NPs at pH 7.4 was 67.7 ± 2.2 %. Under more acidic 
conditions, the amount of Rh123 that appeared in solution was dramatically reduced (37.5 ± 0.8 
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% at pH 6.2 and 11.5 ± 1.0 % at pH 5.5 respectively). This suggests that Rh123 release from 
Eudragit L-100 NPs under reduced acidic conditions present in TB-infected phagosomes will be 
3-fold greater than in non-infected macrophages where lysosomal pH remains between pH 4.7-
5.5. The lag time of Rh123 release observed at pH 7.4 increases the confidence that only a small 
fraction of Eudragit L-100-encapsulated payload will be prematurely released in the alveolar 
region prior to internalization of NPs by AMs. 
To delineate underlying mechanisms that govern release of Rh123 from Eudragit L-100 NPs, 
release profiles were analyzed using various mathematical models. The results from model–
dependent linear and non-linear regression analyses are summarized in Table 4. 
Table 4. Mathematical Assessment of Rh123 Release Kinetics  
 
pH 5.5 
 Zero First Higuchi Hixon Baker Peppas 
R² 0.947 0.974 0.992 0.927 0.983 0.976 
 
pH 6.2 
 Zero First Higuchi Hixon Baker Peppas 
R² 0.921 0.997 0.978 0.975 0.993 0.963 
 
pH 7.4 
 Zero First Higuchi Hixon Baker Peppas 
R² 0.890 0.997 0.868 0.953 0.993 0.821 
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From the correlation coefficients summarized in Table 4, it appears that not only one but several 
different release mechanisms may have contributed to the experimentally determined 
appearance rates of Rh123. To verify the goodness of fit for the various release models, an 
analysis of residuals was performed for each condition and residual plots for each of the 
mathematical models were generated (see Appendix). Limited by the numbers of experimental 
observations, it was concluded that more than one model can adequately explained the release 
kinetics of Rh123 from this NP dispersion. According to the pattern of residuals, however, it 
appeared that Rh123 release at pH 5.5 closely followed the Higuchi model. At pH 6.2, first 
order kinetics adequately described Rh123 release, whereas Rh123 release at pH 7.4 appeared to 
follow first order kinetics and as well as the Baker model. 
 
4.2. Alveolar Macrophages Cell Culture Model 
Eudragit L-100 NPs are predicted to effectively accumulate in AMs in order to maximize 
therapeutic drug concentration against macrophages-resident TB bacteria. The mouse alveolar 
macrophage MH-S cell line was selected for in vitro uptake studies using the fabricated NPs. 
The initial objective was to define an experimental design that assures sufficient cells for 
cellular uptake experiments despite repeated washing. To accomplish this objective, pilot 
experiments were conducted to identify suitable seeding densities and cell attachment periods. 
Total protein concentration after cell lysis was used as a quantitative estimate of cells 
remaining. The correlation between total cellular protein and cell number was assessed using 
linear regression analysis of cells versus protein amount after lysis: 
Total cell protein = 0.0003 x Cell number - 1.1238 
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Figure 11: Optimization of MH-S cell attachment. MH-S cells were seeded at different densities in  
96-well plate and incubated at 37o C (5% CO2). The cell number remaining after 12 hours (Panel A), 24 hours 
(Panel B), and 48 hours (Panel C) with (W) and without (N) washing was estimated using the BCA protein 
assay. Results are shown as mean ± SD (n = 8). 
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The results summarized in Figure 11 suggest that a cell seeding density of 5 x 104 cells/well 
incubated for 48 hours is most resistant to washing manipulations when compared to control 
experiments without washing (p = 0.65). Therefore, all subsequent cell culture experiments 
were performed using a seeding density of 5 x 104 cells/well, and experiments were only 
initiated after incubation period of 48 hours. 
 
 
 
4.2.1. Cell Viability Studies 
To assess the consequences of Eudragit L-100 NP exposure on cell viability, increasing 
concentrations of the NP suspension were incubated with MH-S cell line for up to 6 hours 
before cell viability was estimated using the CellTiter-Glo® Luminescent Cell Viability Assay. 
The results summarized in Figure 12 demonstrated that increasing NP concentrations 
progressively decreased MH-S cells viability even after a short-term incubation period of only  
1 hour. 
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Figure 12: Cytotoxicity of Eudragit L-100 nanoparticles on MH-S cells in vitro. MH-S cells were 
incubated at 37o C (5% CO2) in 96-well plates for 1 hour (Panel A), 2 hours (Panel B), 4 hours (Panel C), and  
6 hours (Panel D) with NP suspension ranging from 0.93 to 4.65 mg Eudragit L-100/mL. Viability data are 
normalized to vehicle-treated control. Dotted line represents fitted line of non-linear regression analysis (see 
Materials and Methods). Results are shown as mean ± SD (n = 3). 
 
To compare time–dependent effects of NP on MH-S cell viability, the concentration inducing 
50% cytotoxicity (IC50) was estimated using non-linear regression analysis (see Materials and 
Methods). The IC50 values for different incubation times are summarized in Table 5. In the 
absence of significant differences between those values, it is concluded that decreased cell 
viability is most likely induced by an acute toxicity mechanism in response to Eudragit L-100 
NP exposure. 
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Table 5. Effect of Eudragit L-100 Nanoparticles on MH-S Cell Viability in vitro  
           Incubation time [hrs] IC50 [mg/mL] 
1 2.82 ± 0.15 
2 2.73 ± 0.16 
4 2.91 ± 0.14 
6 2.83 ± 0.35 
 
   Results are shown as mean ± SD (n = 3). 
 
Based on these data, subsequent cellular uptake studies were performed using a NP 
concentration of 1.62 mg/mL, which is estimated to compromise cell viability <0.1%. 
 
4.2.2. Nanoparticles Uptake by Alveolar Macrophages 
To quantify intracellular accumulation of Eudragit L-100 NPs in MH-S cells, cellular uptake of 
Rh123-loaded NPs was compared to the uptake of a Rh123 solution prepared in DMEM at a 
concentration equivalent to the Rh123 concentration administered as NP suspension. The 
fluorescence signal of intracellular Rh123 was measured spectrofluorometrically before and 
after cells lysis. 
The results summarized in Figure 13 suggest that MH-S cells are capable of internalizing 
Rh123-containing NPs to the same extent as Rh123 dissolved in serum-free cell culture media. 
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Figure 13: Uptake of Rh123-containing Eudragit L-100 NPs in MH-S cells. NP 
suspension and Rh123 solution prepared in serum-free DMEM were incubated with MH-S cells for 
30 minutes. Fluorescence was quantified at EM = 520 nm (EX = 485 nm) before and after lysis of 
cells using RIPA buffer. Fluorescence signal after cell lysis was monitored for up to 18 hours. 
Results are shown as mean ± SD. (n = 6). ** significantly different p < 0.001 
 
It is concluded that cellular uptake of NPs and Rh123 solution in MH-S cells may not require 
specific membrane interactions but rather occurs via non-specific engulfment of extracellular 
fluid. The experiment demonstrated that the captured fluorescence signal of Rh123 significantly 
increased after dissolving the cells with RIPA lysis buffer. This suggests fluorescence 
quenching of Rh123 after cellular uptake due to high concentrations of internalized material 
within small intracellular compartments (e.g., lysosomes). Consequently, accurate 
determination of internalized Rh123 requires destruction of cellular and subcellular 
compartments allowing homogeneous distribution of this fluorescence probe. Time-dependent 
monitoring of the fluorescence signal demonstrated that RIPA buffer instantaneously dissolves 
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all cellular and subcellular membrane structures facilitating accurate quantification of Rh123 
after cell lysis within one hour. 
 
4.2.3. Modulation of Lysosomal pH Values 
One major objective of this research was to assess the impact of acidic lysosomal pH in TB-
infected AMs on NPs uptake and Rh123 release kinetics. Previously, it was recognized that 
fluorescence intensity of FD40 quantitatively changes in response to different pH values. 
Consequently, this fluorescent probe has been widely used to estimate the pH value of 
intracellular compartments, including lysosomes (Ohkuma et al., 1978). To quantify lysosomal 
pH in MH-S cells, a pH-dependent calibration curve of FD40 fluorescence was generated (see 
Figure 14). 
  
 
Figure 14: pH-dependent fluorescence of FD40. The fluorescence of FD40 dissolved at  
1 μg/mL in phosphate buffer pH 3.5-8.5 was measured at EM = 520 nm using EX = 485 nm and 
EX = 460 nm, respectively.  
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From the fluorescence ratio measured at EM = 520 nm using two different EX wavelengths, it is 
evident that the fluorescence of FD40 measured at EX = 485 nm is changing more rapidly under 
basic conditions than the intensity acquired at EX = 460 nm. Using polynomial least square 
regression analysis, the experimental relationship shown in Figure 14 can be mathematically 
described by: 
       Fluorescence FD40 (485/460) = - 0.0173 pH 3 + 0.3183 pH 2 – 1.7085 pH + 3.1481 
This equation was used to estimate lysosomal pH after measuring the EM intensity ratio at EX = 
485 and 460 nm, respectively. 
Prior to lysosomal pH measurement, it was crucial to define experimental conditions that allow 
maximum accumulation of FD40 inside the desired subcellular compartments, which will 
increase quantitative accuracy of lysosomal pH estimates. Figure 15 summarize the effect of 
different extracellular FD40 concentrations and incubation periods on intracellular FD40 
accumulation in MH-S cells. 
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Figure 15: FD40 uptake kinetics in MH-S cells.  FD40 solutions prepared in serum-free 
DMEM were incubated with MH-S cells at 37° C for up to 24 hours. After quenching of 
extracellular FD40 using Trypan blue, fluorescence was quantified spectrofluorometrically at  
EM = 520 nm (EX = 485 nm). Results are shown as mean ± SD (n = 5). 
* significantly different p < 0.05 
 
The results in Figure 15 demonstrate a dose–dependent uptake of FD40 in MH-S cells, with a 
maximum intracellular accumulation of this pH-sensitive macromolecule after a 3-hour 
incubation period using 2 mg/mL of FD40. Prolonged incubation did not significantly increase 
intracellular FD40 levels. Consequently, preincubation of MH-S cells with a 2 mg/mL FD40 
solution for 3 hours was adopted as a standard experimental design for measuring lysosomal pH 
in MH-S cells. 
Since extracellular FD40 was not removed by washing in order to minimize the risk of cell loss, 
Trypan blue was used to quench residual extracellular probe prior to spectrofluorometric 
quantitation of intracellular FD40 (Nuutila et al., 2005). To evaluate the effectiveness of Trypan 
blue in FD40 quenching, different dye concentrations (0.2 - 4 mg/mL) were combined with a 
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FD40 solution that was prepared at 1 mg/mL using phenol red-containing, serum-free DMEM, 
phenol red-free, serum-free DMEM, and PBS. 
 
Figure 16: Quenching efficiency of FD40 using Trypan blue. Fluorescence intensity of FD40 
(1 mg/mL) was measured at EM = 520 nm (EX = 485 nm) and normalized to unquenched control. 
Results are shown as mean ± SD (n = 2). 
 
The data summerized in Figure 16 demonstrated a constant decrease in FD40-associated 
fluorescence signal when combined with increasing Trypan blue concentrations. However, even 
at the highest Trypan blue concentration of 4 mg/mL, which was reported to be safe for use in 
cell culture experiments, a residual FD40 fluorescence signal was detected. Since accurate 
measurement of lysosomal pH critically depends on quenching of extracellular FD40, it was 
concluded that addition of Trypan blue was not a viable approach to accomplish the objective of 
this study. Instead, additional washing steps must be included to eliminate excess extracellular 
FD40 despite the increased risk of removing attached cells during this manipulation. 
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After modification of the experimental procedure required to remove extracellular FD40, it was 
necessary to repeat cellular FD40 uptake studies. In comparison to the 2-hour incubation period, 
intracellular FD40 amount was significantly increased after a 3-hour incubation (Figure 17, 
Panel A). More extended incubation did not augment uptake efficacy. 
 
 
 
Figure 17: Estimation of lysosomal pH in MH-S cells. Panel A: FD40 (2.5 mg/mL) in serum-free DMEM 
was incubated with MH-S cells for up to 4 hours. After removal of extracellular FD40 by washing, intracellular 
FD40 was quantified before and after cell lysis spectrofluorometrically at EM = 520 (EX = 485 nm). Panel B: 
Estimated lysosomal pH value of MH-S cells using FD40 pH-dependent calibration curve. Results are shown as 
mean ± SD. (n = 7). 
* significantly different p <0.05 
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Using the pH-dependent calibration curve of FD40, the lysosomal pH of control MH-S cells 
was estimated to be in the range of pH 4.7 – 5.6 (Figure 17, Panel B), which is consistent with 
previously reported values (Geisow et al., 1981). 
To quantitatively assess cellular uptake and intracellular release of Rh123-containing NPs under 
pH conditions present in the phagosomes of TB-infected macrophages, experimental 
modulation of lysosmal pH was attempted using procedures previously established by several 
research groups (Ohkuma et al., 1978, Poole et al., 1981, and Geisow et al., 1981). 
MH-S cells were treated with different concentrations of NH4Cl which is predicted to elevate 
the pH of lysosomes from pH 5.5 to the desired value of approximately pH 6.2 (Hackam et al., 
1997).  
  
 
 
60 
 
 
 
Figure 18: Lysosomal pH modulation in MH-S cells. NH4Cl solutions prepared in amino acid-free DMEM 
were incubated with MH-S cells for 1 hour in 37° C. Lysosomal pH was estimated using pH-dependent 
fluorescence of intracellular FD40. Amino acid-free DMEM was used as control (see Materials and Methods). 
Panel A: mean estimated pH values of lysosomes after NH4Cl treatment (n = 6). Panel B: effect of 100 mM NH4Cl 
on lysosomal pH of MH-S cells. Results are shown as mean ± SD. (n = 6).  
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The results summarized in Figure 18 Panel A illustrate that NH4Cl concentrations >10 mM 
effectively increased lysosomal pH of MH-S above the resting pH value of 5.5. Incubation with 
100 mM NH4Cl solution raised lysosomal pH to the desired value of 6.2 within 50 minutes. 
Closer examination of the changes induced by 100 mM NH4Cl solution revealed that 
significantly less acidic lysosmal pH values are achieved within 5 minutes (Panel B). Removal 
of external NH4Cl by washing resulted in rapid re-acidification of lysosomes, which is likely 
due to compensotary mechanism induced by the action of acidifying enzymes such as the  
V-ATPase. 
 
4.2.4. Lysosomal pH Effect on Nanoparticles Uptake in MH-S Cells 
After establishing a suitable experimental procedure to modulate lysosomal pH to the less acidic 
value present in TB-infected marophages, it was necessary to investigate whether changes in 
lysosomal pH affect cellular uptake efficiency of MH-S cells. The results summerized in Figure 
19 underline a significant decrease in intracellular accumulation of both Rh123-containing NPs 
as well as Rh123 administered as a solution after cells were treated with 100 mM NH4Cl. 
Cellular lysis still increased the fluorescence intensity of internalized Rh123 supporting the 
earlier hypothesis of quenching due to accumulation in subcellular compartments. 
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Figure 19: Effect of lysosomal pH on internalization efficiency. Rh123–loaded NPs (Panel A) and a 
Rh123 solution prepared a a concentration equivalent to NP-encapsulated Rh123 (Panel B) were incubated with 
MH-S in the presence and absence of 100 mM NH4Cl for 1 hour at 37° C. Intracellular Rh123 was quantified 
before and after cells lysis spectrofluorometricaly at EM = 520 nm (EX = 485 nm). Control cells were subjected to 
amino acid–free DMEM. Results are displayed as mean ± SD. (n = 4). 
* significantly different p <0.05 
 
Whether this reduced cellular uptake capacity after NH4Cl treatment was uniquly associated 
with the use of this chemical or due to the induced increase lysosomal pH requires further 
investigation. Similar to earlier observations, NP uptake as well as Rh123 uptake after 
administration as a solutionwas were reduced equivalently suggesting the possibility of the 
same cellular uptake mechanism. 
MH-S cells incubated with Rh123-containg Eudragit L-100 NPs and the Rh123 solution were 
visually evaluated by confocal microscope in order to investigate whether distinct intracellular 
distribution pattern can be observed. This qualitative methodology could be used to monitor 
different release kinetic of Rh123-containing NPs inside MH-S cells in response to different 
lysosomal pH values. Representitive confocal images are shown in Figure 20 where the 
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presence of the light green color visually underlines successful internalization of Rh123-
containing NPs and Rh123 administered as a solution in MH-S cells (Panel A and C). 
Modulation of lysosomal pH using 100 mM NH4Cl quantitatively reduced cellular uptake of 
extracellular NPs and Rh123 (see Figure 19). However, the difference in quantitative uptake 
using NH4Cl-treated cells is not effectively visible in confocal images (Panel B and D).  
 
Figure 20: Visualization of cellular uptake of Rh123-containing Eudragit L-100 NPs. MH-S cells 
were incubated for 1 hour at 37° C with Rh123-containing Eudragit L-100 NPs or Rh123 solution prepared in 
amino acid-free DMEM in the presence and absence of 100 mM NH4Cl. Representation confocal images were 
acquired at EM = 505-530 nm (EX = 488 nm) using the Zeiss LSM 510 META. Panel A: Rh123-NPs in control 
cells, Panel B: Rh123-NPs in NH4Cl-treated cells, Panel C: Rh123 solution in control cells, and Panel D: Rh123 
solution in NH4Cl-treated cells.  
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It was hypothesized that Rh123 release from intracellular Eudragit L-100 NPs can be visualized 
by a change in subcellular distribution pattern of the highly fluorescent NP that accumulated in 
lysosomes after cellualar internalization. However, comparison of the fluorescence pattern 
acquired by confocal microscopy for Rh123-containing Eudragit L-100 NPs and Rh123 solution 
(Figure 20, Panel A and C) did not support this hypothesis. These unexpected findings revealed 
a limitation of confocal microscope to determine intracellular release kinetics of Rh123-
containing Eudragit L-100 NP in response to different lysosomal pH conditions. 
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5. Discussion  
The emergence of drug-resistant TB strains decreases the effectiveness of conventional drug 
regimens, augments the risk of transmission, and imposes critical conditions for 
immunocompromised individuals. Development of novel drug delivery systems that allow 
spatial and temporal control of drug release in response to unique, disease-associated changes in 
lysosomal pH of TB-infected AMs offer the advantage for selective intervention at the target 
site. Simultaneously, drug exposure of healthy tissues will be limited, which is anticipated to 
decrease adverse events. The less acidic environment present in the phagosome of M. 
tuberculosis-infected AMs (i.e., pH = 6.2 instead of pH = 4.7-5.5) was used as scientific 
rationale for exploring nanoparticle formulations fabricated using the pH-responsive polymer 
Eudragit L-100. The main hypothesis driving this research was that NP payload is preferentially 
released inside the phagosome of infected AMs where the less acidic environment favors 
accelerated degradation of the acrylic acid/methylacrylate co-polymer. Although uninfected 
AMs may internalize these NPs at the same rate, it was predicted that payload release will be 
significantly slower due to the more acidic environment. Consequently, drug exposure of 
uninfected AMs will be limited resulting in greater safety for patients. 
The fluorescent dye Rh123 was selected as surrogate payload to facilitate rapid fluorometric 
quantitation of the encapsulation efficiency in Eudragit L-100 NPs, in vitro release under 
different pH conditions, and intracellular accumulation in MH-S cells. Rh123 exhibits 
physicochemical characteristics comparable to the anti-TB drug rifampicin, specifically with 
regards to molecular lipophilicity as demonstrated by similar solubility in organic solvents such 
as methanol, ethanol, and dimethyl sulfoxide (Santa Cruz Biotechnology, 2015). 
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Rh123 containing–Eudragit L100 NPs were fabricated using the nanoprecipitation method. 
Conventionally, the polymer is dissolved in a suitable organic solvents including acetone 
(Devarajan et al., 2007), methanol (Karve et al., 2011), and ethanol (Tang et al., 2011). To 
enable sufficient solubility of Eudragit L-100 and the fluorescent dye, an acetone/water mixture 
(97:3, v/v) was selected for this research. Acetone was also preferred because of its high 
evaporation rate at room temperature (vapor pressure at 25 °C = 229 mm Hg (DDBST, 2015)), 
which was predicted to limit residual solvent in the NP preparation that may induce a cytotoxic 
effect in MH-S cells. 
To maximize exposure of TB-infected AMs to this novel stimulus-induced drug delivery 
system, fabricated NPs were intended for administration via inhalation. Consequently, it was 
essential to optimize fabrication conditions with a specific focus on particle size as this 
parameter predominantly defines pulmonary deposition after inhalation (Labiris et al., 2003). 
Previous research focusing on pulmonary administration of insulin-loaded liposomes in mice 
identified a critical particle diameter of approximately 250 nm for successful deposition in the 
alveolar region (Huang et al., 2006). Larger particles accumulated at extrathoracic sites such as 
the larynx, whereas particles ≤ 50 nm were reported to induce autophagy of macrophages (Eidi 
et al., 2011). The efforts of extensive optimization experiments identified a polymer feed of  
100 mg of Eudragit L-100 combined with a 3-hour magnetic stirring period that result in in NPs 
exhibiting a desired diameter of approximately 250 nm. At the end of the fabrication process, 
Rh123-containing NPs were subjected to an additional purification step by dialysis in 0.3 μM 
HCl (pH = 3.5) to remove surface-adsorbed Rh123 that was predicted to induce an undesired 
burst effect after administration. The acidic dialysis medium was selected with the objective to 
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limit Eudragit L-100 degradation as well as premature release of the encapsulated payload 
during purification. 
Accurate analytical determination of encapsulated Rh123 in Eudragit L-100 NPs requires 
complete dissolution of the polymer matrix and subsequent release of the fluorescent dye into 
the dissolution vehicle. Initially, several organic solvents were evaluated based on available 
solubility data for Eudragit L-100. Surprisingly, particle suspensions prepared in these solvents 
contained a significant fraction of larger aggregates ≥ 1 μm. Billmeyer and colleagues 
hypothesized that the process of polymer dissolution is a sequential process involving polymer 
swelling followed by dissolution of the solvent-accessible polymer strands (Billmeyer Jr., 
1984). Eudragit L-100 is a copolymer comprised of methacrylic acid and methyl methacrylate at 
a molar ratio of 1:1. Consequently, it was predicted that inter- and intramolecular forces such as 
hydrogen bonding and dipole-dipole interactions govern solvation. As shown in Figure 7, NP 
dispersion prepared in acetone, isopropanol, and ethanol contained large aggregates >1 μm. 
These results suggested that cohesive polymer-polymer forces between Eudragit L-100 NPs 
were greater than adhesive polymer-solvent forces. Upon addition of NaOH, the fraction of 
large aggregates disappeared most likely due to ionic forces between hydroxyl groups and 
carboxylate groups of deprotonated methacrylic acid. Ultimately, base-catalyzed ester bond 
hydrolysis of the methylmethacrylate backbone may have led to the complete dissolution of the 
Eudragit L-100 NPs (Taylor, 2002). 
The release properties of Rh123 from fabricated Eudragit L-100 NPs were assessed using 
phosphate buffer solution adjusted to pH values that were representative of the highest pH value 
recorded inside lysosomes of uninfected control macrophages (pH 5.5) (Butor et al., 1995), the 
lowest pH value measured in M. tuberculosis–containing phagosomes (pH 6.2) (Sturgill-
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Koszycki et al., 1994), and the pH value estimated within the bronchial lumen (pH 7.4). Various 
mathematical models were used to delineate the mechanisms governing Rh123 release from 
Eudragit L-100 NPs under different pH conditions. The highest correlation coefficients from 
regression analyses and residual profiles obtained for first-order release kinetics suggested 
polymer backbone erosion induced by partial ionization of Eudragit L-100 carboxylate groups 
as a dominant mechanism of payload release at pH 6.2 and 7.4. Model-dependent analysis of 
release kinetics at pH 5.5 revealed the highest correlation for the Higuchi model indicating that 
Rh123 diffusion through the intact NP is dominating payload release under more acidic 
conditions where carrier erosion is minimal. The analysis of residuals illustrated that not only 
one but multiple mathematical models may explain the release kinetics of Rh123 from Eudragit 
L-100 NPs at pH values tested. More extended studies will be required to collect a greater 
number of data points that will increase confidence in model-dependent correlation analyses. 
Cellular uptake experiments using Rh123-containing NPs and Rh123 solution revealed that 
MH-S cells contained the same amount of Rh123 irrespective to the delivery system applied. 
There are several mechanisms known to facilitate intracellular uptake. However, phagocytosis is 
predicted to dominate internalization of particulate material in macrophages (Sahay et al., 
2010). This uptake mechanism is triggered by an interaction of foreign material with cell 
surface receptors such as mannose and scavenger receptors. Other receptors participating in this 
recognition include the complement receptor and Fc receptors, which can bind to complement 
molecules or immunoglobulins adsorbed to the particle surface (Sahay et al., 2010). Factors 
such as NP material, size, and shape, as well as cell type determine the magnitude of NP uptake 
by phagocytosis (Kuhn et al., 2014). Whether or not receptors were involved in MH-S uptake of 
Eudragit L-100 NPs is unclear. Future experiments using various pharmacological inhibitors of 
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cellular internalization mechanisms may allow further delineation of the underlying mechanism 
of NP uptake in this model system of TB-infected AMs (Ivanov, 2008). 
In contrast, cellular uptake of solutes dissolved in extracellular fluid is primarily accomplished 
via pinocytosis, which involves engulfment of an extracellular volume within a small membrane 
vesicle. This uptake mechanism is actin-driven and involves protrusions of the outer cell 
membrane followed by fusion with the cell membrane (Doherty et al., 2009). It was predicted 
that uptake of Rh123 solution will be predominantly accomplished by pinocytosis. Comparable 
extent of intracellular Rh123, however, requires further assessment of this hypothesis.  
The discovery that intracellular Rh123 concentrations increase after dissolving cellular and 
subcellular compartment using RPA lysis buffer suggested quenching of internalized 
fluorescent dye due to confined accumulation inside a small cellular compartment such as the 
lysosome. Solubilization of these compartments allows homogeneous distribution of Rh123 
within the cell lysate and, thus, accurate quantitation using fluorescence spectrophotometry.  
FITC-labelled Dextran (FD40; M.W. = 40,000) is a commercially available fluorescent 
compound that has been widely used for the assessment of lysosomes pH due to preferential 
sequestration these organelles (Geisow et al., 1981). The measured fluorescence intensity of this 
probe using emission filters of 520 nm is very sensitive to the pH, especially in the range of 5 to 
7.5. Ohkuma and colleagues showed that the FD fluorescence spectrum displays a sharp peak in 
alkaline medium upon excitation with 495 nm. Under more acidic conditions, this peak intensity 
decreases and is replaced by another peak at 450 nm (Ohkuma et al., 1978). Consequently, 
FD40 fluorescence was measured in PBS at different pH values using emission filter 520 nm 
with excitation filters of 485 nm (bandwidth = 10 nm) and 460 nm (bandwidth = 10 nm). These 
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excitation filters possess the same fluorescence detection sensitivity as determined by 
Fluorescence SpectraViewer (Life Technologies, Grand Island, NY). Subsequently, the yield 
ratio 485/460 was calculated, and calibration curve was used to predict the pH of MH-S alveolar 
macrophages lysosomes. 
To simulate lysosomal pH conditions of M. tuberculosis-infected macrophages, MH-S 
macrophages were subjected to different concentrations of NH4Cl that has been used previously 
to increase lysosomal pH value in different cell lines (Ohkuma et al., 1978, Poole et al., 1981, 
and Geisow et al., 1981). NH4Cl was dissolved in amino acid free- and fetal bovine serum-free 
DMEM to limit undesired ammonia production due to cellular metabolism of these compounds 
(Ohkuma et al., 1978). Experimental data summarized in Figure 18 confirm a concentration-
dependent increase in lysosomal pH. This effect was reversed when the NH4Cl solution was 
removed by washing. The mechanism by which NH4Cl affects lysosomal pH is attributed to the 
free base (i.e. NH3) (De Duve et al., 1974). Upon incubation with macrophages, ammonia 
diffuses across the cell membrane entering the lysosomal compartment. The acidic environment 
inside the lysosomes, which is maintained by acidifying enzymes, will facilitate NH3 ionization 
to NH4+ that will be trapped inside the lysosomes as an ionized species. The ammonia 
concentration available for neutralization of the acidic environment in lysosomes is defined by 
the extracellular NH4Cl concentration used. Upon removal of extracellular NH4Cl solution, 
NH4+ will slowly leak out of the lysosomes, and enzymes/carriers like Na+/K+-ATPase and  
V-ATPase will continue to acidify the lumen until lysosomal pH conditions are re-established. 
Based on the predicted, distinctly different cellular uptake mechanisms for NPs and solutions, it 
was hypothesized that confocal microscope may be a suitable qualitative technique to visually 
distinguish intracellular Rh123 after release from NPs. As the results from comparative uptake 
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experiments using Rh123-containing NPs and Rh123 solution did not reveal a significantly 
different intracellular distribution pattern (see Figure 20), alternative approaches as discussed in 
the Future Directions section must be considered. 
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6. Conclusions 
Therapeutic efficacy of anti-TB drugs is limited due to the requirement for prolonged drug 
administration and debilitating drug-induced adverse effects that promote patients non-
compliance with drug regimens, and consequently, treatment failure. Nanotechnology-based 
SMART drug delivery systems may offer unique advantages in reducing incidence of drug-
resistant TB while limiting undesirable adverse events that are usually associated with non-
selective drug distribution after systemic administration of conventional anti-TB drugs. 
In this research, the nanoprecipitation method was successively applied to fabricate Rh123-
containing Eudragit L-100 NPs of approximately 250 nm in diameter, which are suitable to 
reach AMs after pulmonary administration. Eudragit L-100 concentrations 1.62 mg/mL did not 
induce significant cytotoxicity in MH-S cells. Furthermore, experimental conditions were 
established to mimic less acidic lysosomal environment present in TB-infected macrophages 
using 100 mM NH4Cl solution. 
Rh123 release from Eudragit L-100 NPs was pH-dependent with a 3-fold greater release at  
pH 6.2 than at pH 5.5. These data suggest significantly faster release of NP-encapsulated 
payload in TB-infected AMs that harbor M. Tuberculosis inside their phagosomes. In the 
absence of significant burst release at pH 7.4, it is predicted that NPs will be internalized by 
AMs after pulmonary administration without premature release of the encapsulated payload in 
the lumen of alveoli. 
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7. Future Directions 
It was anticipated that confocal microscopy will be a suitable technology to qualitatively 
differentiate between NP-associated and released Rh123 according to a significantly different 
intracellular fluorescence distribution pattern. Unfortunately, the results from this study did not 
support this hypothesis leaving a major question of this research unanswered. Future effort 
should be directed toward suitable methodologies that facilitate qualitative and quantitative 
measurement of intracellular distribution of NP-encapsulated payload. 
It is proposed that cell fractionation, which physically separate subcellular compartments (de 
Duve et al., 1953), may offer the best chances for success. In general, this technique is 
comprised of two separate centrifugation steps: (1) differential centrifugation, which relies on 
the difference in terminal velocity of cellular components, will separate cellular components on 
the basis of size, mass and density into several zones (de Duve et al., 1953). Differential 
centrifugation is not organelle-specific because each zone contains several types of organelles 
having similar sedimentation velocities. Therefore, density gradient centrifugation will be 
required to separate lysosomes from other organelles. Purified lysosomes can then be incubated 
with Rh123-NPs and release kinetics of Rh123 from Eudragit L-100 NP can be quantified 
spectrofluorometrically as Rh123 diffuses out of the lysosomes into the suspension vehicle. 
To circumvent this tedious centrifugation methodology, Eudragit L-100 NPs containing 
rifampicin could be prepared. Release kinetics and therapeutic efficacy can be evaluated in vitro 
by incubating rifampicin-NPs with TB-infected AMs collected from TB-infected animals. 
Alternatively, rifampicin-containing Eudragit L-100 NPs can be administered via inhalation to 
animals, and AMs uptake as well as therapeutic efficacy can be assessed by sacrificing animals 
at predetermined time intervals. In both cases, macrophages will be collected, lysed, and 
 
 
74 
 
rifampicin concentrations determined using an appropriate quantitative methodology such as 
high-performance liquid chromatography (Chuan et al., 2012). Pharmacological efficacy of 
rifampicin-containing NPs can be assessed by histopathological examination of the lungs and 
microbiological determination of viable bacteria (Suarez et al., 2001). 
In an expansion of the current research, it is also important to explore future opportunities of 
this nanotechnology-based SMART drug delivery system for hydrophilic anti-TB drugs, 
including, but not limited to, INH and streptomycin. 
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APPENDIX 
Residuals Plots generated from regression analyses performed with different mathematical 
models using pH-dependent Rh123 release data. 
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b) pH 6.2 
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c) pH 7.4 
* 
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